AHA: Once-Daily Edoxaban Seems Safe for Pediatric Cardiac Patients

Rates of clinically relevant bleeding similar between groups receiving edoxaban or standard-of-care anticoagulation

child heart
Adobe Stock

FRIDAY, Nov. 4, 2022 (HealthDay News) -- Once-daily edoxaban seems safe and effective for pediatric patients with cardiac disease, according to a study presented at the American Heart Association Scientific Sessions 2022, held from Nov. 5 to 7 in Chicago.

Michael A. Portman, M.D., from Seattle Children's Hospital, and colleagues conducted a phase 3 trial in patients younger than 18 years with cardiac diseases who had an increased risk for thromboembolism. One hundred sixty-eight children were randomly assigned in a 2:1 ratio to either age- and weight-based oral edoxaban once daily or standard-of-care (SOC) anticoagulation for three months. Both groups continued in a one-year extension with edoxaban.

The researchers found that the clinically relevant bleeding (CRB) event rates were similar between the groups during the main period. In each group, one patient experienced a nonmajor CRB. Treatment-emergent adverse events occurred in 46.8 and 41.4 percent of patients treated with edoxaban and SOC, respectively. Two thromboembolism events were experienced by one patient treated with SOC. A total of 152 participants continued in the extension phase; one CRB event occurred (0.7 percent; trauma-related) and four thromboembolisms occurred (2.8 percent).

"If a child is having difficulty with anticoagulant treatment -- for instance becoming tired of the twice-daily injections -- it would be reasonable to discuss with the child's physician or health care team about whether edoxaban is an option," Portland said in a statement.

Several authors disclosed ties to pharmaceutical companies, including Daiichi Sankyo, which manufactures edoxaban and funded the study.

Press Release

More Information

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on November 04, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ